2026 Annual Meeting | Industry Therapeutic Update from Eisai, Inc.:Smoldering Alzheimer's Disease: The Ongoing Benefit of Addressing Multiple Pathologies

Date Monday 04/20/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Nathaniel Chin, MD

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Join us for an exciting symposium where we will introduce and explore the concept of smoldering Alzheimer's disease (AD). We will guide attendees through the meaning of “smoldering", which can be described as an insidious constellation of pathological changes that drives disease progression over time. While it is a novel concept in AD, smoldering is familiar across many chronic diseases, including multiple myeloma, multiple sclerosis, and lupus. The process of smoldering AD will be explored from the preclinical phase, characterized by the silent accumulation of Aβ42 oligomers and protofibrils, to the toxic downstream events that unfold and extend beyond the formation of amyloid plaque. Drivers of continued disease progression in Smoldering AD include toxic soluble amyloid species, hyperphosphorylated tau, inflammation, and neurodegeneration. This session will highlight the clinical importance of smoldering AD as well as its potential to guide the selection of appropriate blood-based biomarkers.
In a separate session during this timeframe, we will explore how an anti-amyloid therapy addresses AD pathophysiological processes, including and extending beyond plaque removal. We will review the clinically meaningful benefit of ongoing therapy as evidenced by a placebo-controlled trial, post-hoc analyses, open-label extension data, and real-world evidence from clinical practice.
A meal will be offered as part of the event.
This program is NOT accredited for continuing education by any organization. Additionally, this Industry Therapeutic Update program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2026 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
The speakers are presenting on behalf of and are paid consultants for Eisai.
Biogen are a co-sponsor for the second session relating to anti-amyloid therapy.
© 2026 Eisai | M2563 | January 2026

CME Available No CME available

Event Timeline
06:00 PM - 08:00 PM CDT	Speaker	Eisai, Inc.

Faculty Disclosures
Nathaniel Chin, MD	No disclosure on file
Adam J. Wolff, MD	No disclosure on file
Babak Tousi, MD	No disclosure on file
Marwan N. Sabbagh, MD, FAAN	Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.

��ɫ��

��ɫ��